Development of an optimized and practical pharmacokinetics/pharmacodynamics analysis method for aztreonam/nacubactam against carbapenemase-producing K. pneumoniae

Background Nacubactam, a new beta-lactamase inhibitor with antibacterial activity, is being developed as a single drug to be co-administered with cefepime or aztreonam. However, determining pharmacokinetics/pharmacodynamics (PK/PD) parameters in beta-lactam/beta-lactamase inhibitor combinations remains challenging. We aimed to establish a practical PK/PD analysis method for aztreonam/nacubactam that incorporates instantaneous MIC (MICi). Methods Based on chequerboard MIC measurements, MICi of aztreonam against carbapenemase-producing Klebsiella pneumoniae in the presence of nacubactam was simulated. Results The mean change in the bacterial count of thigh-infected mice in an in vivo PD study was plotted based on %fT(>MICi) and analysed using the inhibitory effect sigmoid I-max model. fT(>MICi) calculated from the PK experiments showed a high correlation with the in vivo bactericidal effect, suggesting that fT(>MICi) is the optimal PK/PD parameter for aztreonam/nacubactam. The target values of fT(>MICi) achieving growth inhibition, 1 log(10) kill and 2 log(10) kill, were 22, 38% and 75%, respectively. Conclusions The PK/PD analysis method proposed in this study is promising for determining practical PK/PD parameters in combination therapy. In addition, this is the first report of aztreonam/nacubactam showing a potent in vivo therapeutic effect against NDM-producing K. pneumoniae.

Automated summary

This study aimed to establish a practical PK/PD analysis method to determine the practical PK/PD parameters of aztreonam/nacubactam. It was found that fT(>MICi) is the optimal PK/PD parameter for aztreonam/nacubactam and is highly correlated with in vivo bactericidal effect.